• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CEO, Medicare Advantage Reynoso Jamie L. covered exercise/tax liability with 6,366 shares, decreasing direct ownership by 0.19% to 3,263,768 units (SEC Form 4)

    4/7/25 4:40:23 PM ET
    $CLOV
    Medical Specialities
    Health Care
    Get the next $CLOV alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Reynoso Jamie L.

    (Last) (First) (Middle)
    C/O CLOVER HEALTH INVESTMENTS, CORP.

    (Street)
    NOT APPLICABLE DE 19801

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    CLOVER HEALTH INVESTMENTS, CORP. /DE [ CLOV ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    CEO, Medicare Advantage
    3. Date of Earliest Transaction (Month/Day/Year)
    04/03/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Class A Common Stock 04/03/2025 F 6,366(1) D $3.51 3,263,768 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents shares of Class A Common Stock that were automatically withheld to cover tax obligations due to the vesting on April 3, 2025, of 6.25% of the restricted stock units ("RSUs") granted to the Reporting Person on January 3, 2023, and originally reported on a Form 4 filed on January 5, 2023. The remaining RSUs will vest in equal quarterly installments, with the final vesting occurring on January 3, 2027, in each case subject to the continued service of the Reporting Person on each such vesting date.
    Remarks:
    /s/Peter J. Rivas as attorney-in-fact for Jamie L. Reynoso 04/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $CLOV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLOV

    DatePrice TargetRatingAnalyst
    12/17/2024$6.00Buy
    Craig Hallum
    10/7/2024$4.00Neutral
    UBS
    2/25/2022$3.00 → $2.50Market Perform
    SVB Leerink
    2/2/2022$7.00 → $3.00Underperform → Market Perform
    Cowen & Co.
    2/2/2022$6.00Buy
    Canaccord Genuity
    1/19/2022$3.00Market Perform
    SVB Leerink
    1/10/2022$9.00 → $3.50Neutral
    Citigroup
    1/7/2022$9.00 → $3.50Neutral → Underperform
    Credit Suisse
    More analyst ratings

    $CLOV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Garipalli Vivek bought $999,596 worth of shares (531,700 units at $1.88), increasing direct ownership by 61% to 1,409,267 units (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      8/13/24 4:06:53 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Director Garipalli Vivek bought $1,000,426 worth of shares (877,567 units at $1.14) (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      6/20/24 4:03:32 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Loengard Anna U bought $25,672 worth of shares (27,085 units at $0.95) (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      5/20/24 6:57:29 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Insider purchases explained

    Analytical look into recent insider purchases

    See more
    • Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

      The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

      6/20/24 6:36:05 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on Clover Health with a new price target

      Craig Hallum initiated coverage of Clover Health with a rating of Buy and set a new price target of $6.00

      12/17/24 8:33:41 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • UBS initiated coverage on Clover Health with a new price target

      UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00

      10/7/24 7:45:42 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • SVB Leerink reiterated coverage on Clover Health Investments with a new price target

      SVB Leerink reiterated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $2.50 from $3.00 previously

      2/25/22 5:03:33 AM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • General Counsel & Secretary Soares Karen covered exercise/tax liability with 27,293 shares, decreasing direct ownership by 2% to 1,267,781 units (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      5/2/25 4:37:46 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • CEO, Counterpart Health Wai Conrad covered exercise/tax liability with 26,593 shares, decreasing direct ownership by 0.81% to 3,236,946 units (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      5/2/25 4:34:22 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • CEO, Medicare Advantage Reynoso Jamie L. covered exercise/tax liability with 25,659 shares, decreasing direct ownership by 0.79% to 3,238,109 units (SEC Form 4)

      4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

      5/2/25 4:33:22 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance

      First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-yearFirst quarter 2025 Total revenues of $462 million, up 33% year-over-yearMedicare Advantage medical costs are in line with expectations, underscoring the strength of Clover's technology-first care management modelMeaningful improvement across first quarter 2025 profitability metrics: GAAP Net loss of $1 million, as compared to a GAAP Net loss of $19 million a year agoAdjusted EBITDA of $26 million, up 279% year-over-yearAdjusted Net income of $25 million, up 322% year-over-year Improved Full Year 2025 Guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year

      5/6/25 4:05:00 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Tech That Listens, Learns, and Diagnoses: AI's Breakout Moment in Healthcare

      USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, May 6, 2025 /PRNewswire/ -- Healthcare is quickly evolving into a digital-first operation, where top executives in the sector are doubling down on artificial intelligence, automation and analytics to reduce costs and improve billing accuracy. This is according to results of a survey from Everest Group (and supported by Omega Healthcare), which showed 85% of senior healthcare executives believe AI will improve efficiencies over the next five years. Now that multitasking AI Agents are being referred to as hospitals' newest "employees", AI-powered electronic noses are detecting scents for health and enviro

      5/6/25 9:45:00 AM ET
      $AMZN
      $CLOV
      $TDOC
      Catalog/Specialty Distribution
      Consumer Discretionary
      Medical Specialities
      Health Care
    • Primary Care Physician Use of Counterpart Assistant Technology Associated with Better Health Outcomes in Patients with Congestive Heart Failure

      WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company") and a leading AI-powered physician-enablement platform, today released research demonstrating how Counterpart Assistant ("CA") use is associated with better management of congestive heart failure ("CHF"). The analysis, titled "Driving Clinical Excellence in Chronic Disease: Counterpart Assistant's Role in Heart Failure Care," details the significant positive association among CHF patients between better clinical care and lower hospitalizations, and having a relationship with a PC

      5/1/25 4:30:00 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

      SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

      11/12/24 2:31:31 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Clover Health Investments Corp.

      SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

      11/4/24 11:25:56 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Clover Health Investments Corp. (Amendment)

      SC 13G/A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Subject)

      7/7/23 4:35:52 PM ET
      $CLOV
      Medical Specialities
      Health Care

    $CLOV
    Leadership Updates

    Live Leadership Updates

    See more

    $CLOV
    Financials

    Live finance-specific insights

    See more

    $CLOV
    SEC Filings

    See more
    • Clover Health Appoints Industry Veteran as Chief Medical Officer of Medicare Advantage

      WILMINGTON, Del., April 07, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced the appointment of Dr. Shelly Gupta as Chief Medical Officer ("CMO"). Dr. Gupta will oversee Clover's innovative clinical operations, quality initiatives, pharmacy operations, and precision-based chronic disease management programs, directly focusing on patient choice, provider autonomy, and delivering transparent, value-driven healthcare. Dr. Gupta brings extensive healthcare experience to Clover as a trained family practice physician with over a decade of experience in Medicare Advantage leadership and a proven record of enhanc

      4/7/25 4:05:00 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Counterpart Health Names David Tsay M.D., Ph.D as Chief Medical Officer

      FRANKLIN, Tenn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a leading AI-powered physician enablement platform, today announced the appointment of David Tsay M.D., Ph.D as Chief Medical Officer (CMO). Dr. Tsay will play a key role in advancing Counterpart's clinical strategy and product roadmap for Counterpart Assistant, the company's proprietary AI-powered physician enablement software platform that empowers providers to deliver high-quality, cost-effective care. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"). David Tsay is a distinguished physician executive with deep expertise and over two decades of ex

      10/8/24 6:15:00 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health Appoints Seasoned Healthcare Executive as Chief Operating Officer for Medicare Advantage Operations

      FRANKLIN, Tenn., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health" or "Clover"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph Brand as Chief Operating Officer (COO) for its Medicare Advantage (MA) plan. Mr. Brand will oversee core MA operations and drive performance improvements, with a focus on improving healthcare delivery in New Jersey by leveraging operational efficiencies and technological innovation. Mr. Brand brings nearly 20 years of healthcare leadership experience, having held prominent positions in healthcare operation

      9/26/24 4:00:00 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health Reports First Quarter 2025 Results and Improves Full Year 2025 Guidance

      First quarter 2025 Medicare Advantage membership of 103,418, up 30% year-over-yearFirst quarter 2025 Total revenues of $462 million, up 33% year-over-yearMedicare Advantage medical costs are in line with expectations, underscoring the strength of Clover's technology-first care management modelMeaningful improvement across first quarter 2025 profitability metrics: GAAP Net loss of $1 million, as compared to a GAAP Net loss of $19 million a year agoAdjusted EBITDA of $26 million, up 279% year-over-yearAdjusted Net income of $25 million, up 322% year-over-year Improved Full Year 2025 Guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year

      5/6/25 4:05:00 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health to Report First Quarter 2025 Financial Results on May 6, 2025

      WILMINGTON, Del., April 08, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will report first quarter 2025 financial results after market close on Tuesday, May 6, 2025. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on May 6, 2025, to discuss Clover Health's first quarter 2025 business and financial results. First Quarter 2025 Conference Call and Webcast Details: What: Clover Health's First Quarter 2025 Earnings Conference CallWhen: Tuesday, May 6, 2025, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-274-8461 (for U.S. callers) or

      4/8/25 4:05:00 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health Reports Fourth Quarter and Full Year 2024 Results; Provides Full Year 2025 Guidance

      Full year 2024 GAAP Net loss from continuing operations improves by $164 million year-over-year Full year 2024 Adjusted EBITDA of $70 million, representing an increase of $112 million year-over-year Company well positioned to invest in membership growth and Clover Assistant technology, while maintaining strong profitability Issues full year 2025 guidance: Average Medicare Advantage membership of 103,000 - 107,000, representing 30% growth year-over-year at the midpointInsurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpointAdjusted EBITDA profitability between $45 million and $70 millionAdjusted Net income between

      2/27/25 4:05:00 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Clover Health Investments Corp.

      10-Q - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

      5/9/25 8:05:31 AM ET
      $CLOV
      Medical Specialities
      Health Care
    • Clover Health Investments Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

      5/6/25 4:06:54 PM ET
      $CLOV
      Medical Specialities
      Health Care
    • SEC Form DEFA14A filed by Clover Health Investments Corp.

      DEFA14A - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

      4/28/25 4:06:15 PM ET
      $CLOV
      Medical Specialities
      Health Care